Mariaelena Pierobon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8178736/publications.pdf

Version: 2024-02-01

68 papers	3,997 citations	218677 26 h-index	123424 61 g-index
77 all docs	77 docs citations	77 times ranked	9326 citing authors

#	Article	IF	Citations
1	Multiâ€omic molecular profiling guideâ€™s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial. Molecular Oncology, 2022, 16, 104-115.	4.6	6
2	Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. Molecular Cancer Research, 2022, 20, 114-126.	3.4	11
3	Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Research, 2022, 82, 586-598.	0.9	27
4	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 762-774.	4.1	9
5	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nature Cancer, 2022, 3, 837-851.	13.2	9
6	Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 upâ€regulation. Molecular Oncology, 2021, 15, 1130-1145.	4.6	18
7	Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models. International Journal of Molecular Sciences, 2021, 22, 2819.	4.1	1
8	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. IScience, 2021, 24, 102757.	4.1	20
9	Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. Journal of Experimental and Clinical Cancer Research, 2021, 40, 198.	8.6	27
10	Integrated multi-omic analyses reveals clinical relevance of endometrial cancer cell line models. Gynecologic Oncology, 2021, 162, S11.	1.4	1
11	Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas. Genes, 2021, 12, 1402.	2.4	3
12	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
13	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Journal of Biological Chemistry, 2021, 297, 101335.	3.4	14
14	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Reports, 2021, 37, 110060.	6.4	14
15	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro-Oncology, 2020, 22, 70-83.	1.2	12
16	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	9.4	820
17	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
18	Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discovery, 2020, 10, 288-305.	9.4	91

#	Article	IF	Citations
19	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
20	The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow. Clinical Proteomics, 2020, 17, 9.	2.1	9
21	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. IScience, 2019, 21, 341-358.	4.1	29
22	Utilization of Proteomic Technologies for Precision Oncology Applications. Cancer Treatment and Research, 2019, 178, 171-187.	0.5	15
23	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	3.4	40
24	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	30.7	476
25	Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. Pancreas, 2019, 48, 894-903.	1.1	8
26	Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active. Blood, 2019, 134, 1388-1388.	1.4	3
27	Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. Molecular Cancer Therapeutics, 2018, 17, 355-367.	4.1	27
28	Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future. Expert Review of Proteomics, 2018, 15, 851-853.	3.0	3
29	An exploratory study examining how nano-liquid chromatographyâ€“mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. BMC Medicine, 2018, 16, 170.	5.5	8
30	Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience.. Journal of Clinical Oncology, 2018, 36, 1077-1077.	1.6	3
31	Reverse Phase Protein Microarrays. Methods in Molecular Biology, 2017, 1606, 149-169.	0.9	55
32	Enrichment of PI3K-AKTâ€“mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clinical Cancer Research, 2017, 23, 4919-4928.	7.0	74
33	MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair. Journal of Thoracic Oncology, 2017, 12, S360-S361.	1.1	0
34	Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Scientific Reports, 2017, 7, 7066.	3.3	68
35	Protein network construction using reverse phase protein array data. Methods, 2017, 124, 89-99.	3.8	5
36	Kinase-driven metabolic signalling as a predictor of response to carboplatinâ€“paclitaxel adjuvant treatment in advanced ovarian cancers. British Journal of Cancer, 2017, 117, 494-502.	6.4	10

#	Article	IF	Citations
37	Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. Oncotarget, 2017, 8, 48534-48544.	1.8	7
38	Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. Oncotarget, 2017, 8, 83343-83353.	1.8	6
39	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. Cancer Drug Discovery and Development, 2016, , 109-124.	0.4	0
40	Network-based analysis of reverse phase protein array data. , 2016, , .		0
41	A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Molecular Oncology, 2016, 10, 1585-1594.	4.6	21
42	Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response. EcoHealth, 2016, 13, 200-212.	2.0	64
43	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell, 2016, 29, 75-89.	16.8	191
44	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. Proteomics - Clinical Applications, 2015, 9, 928-937.	1.6	32
45	Phosphorylation, Signaling, and Cancer: Targets and Targeting. BioMed Research International, 2015, 2015, 1-3.	1.9	10
46	Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting. Journal of the National Cancer Institute, 2015, 107, djv059.	6.3	86
47	Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy. Proteomics, 2015, 15, 365-373.	2.2	22
48	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget, 2015, 6, 32368-32379.	1.8	25
49	Integration of Protein Network Activation Mapping Technology for Personalized Therapy. , 2014, , 367-383.		0
50	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Review of Proteomics, 2014, 11, 237-249.	3.0	9
51	A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 147, 579-588.	2.5	73
52	Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2013, 137, 307-314.	2.5	281
53	Alcohol consumption and violence among Argentine adolescents. Jornal De Pediatria (VersÃ£o Em) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	2
54	Reverse Phase Protein Microarrays and Their Utility in Drug Development. Methods in Molecular Biology, 2013, 986, 187-214.	0.9	10

#	Article	IF	Citations
55	Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clinical and Experimental Metastasis, 2013, 30, 309-316.	3.3	20
56	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clinical Cancer Research, 2012, 18, 6426-6435.	7.0	110
57	Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. Clinical Colorectal Cancer, 2012, 11, 268-274.	2.3	6
58	Reverse-Phase Protein Microarrays. Methods in Molecular Biology, 2012, 823, 215-235.	0.9	30
59	Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). Journal of Proteome Research, 2011, 10, 774-779.	3.7	10
60	Reverse Phase Protein Microarrays for Clinical Applications. Methods in Molecular Biology, 2011, 785, 3-12.	0.9	17
61	Mechanism of Cell Adaptation. Cancer Journal (Sudbury, Mass), 2011, 17, 89-95.	2.0	162
62	Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Laboratory Investigation, 2010, 90, 787-796.	3.7	59
63	Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clinical Colorectal Cancer, 2009, 8, 110-117.	2.3	49
64	Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy. Journal of Proteome Research, 2008, 7, 1508-1517.	3.7	128
65	A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process. Molecular and Cellular Proteomics, 2008, 7, 1998-2018.	3.8	187
66	Laser capture microdissection technology. Expert Review of Molecular Diagnostics, 2007, 7, 647-657.	3.1	161
67	Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Review of Molecular Diagnostics, 2007, 7, 625-633.	3.1	77
68	Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy. , 0, , 475-485.		0